News
Jubilation for Biogen, Eisai as FDA says 'yes' to aducanumab
Biogen and Eisai have defied the naysayers and secured an historic FDA approval for their amyloid-targeting antibody aducanumab as the first-ever disease-modifying treatment for Alzheimer's
